Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPT0B640 in Patients With COVID-19 Infection
NCT04526717Phase 1Withdrawn
- Sponsor
- J INTS BIO
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of MPT0B640 in coronavirus disease 2019 (COVID-19), sponsored by J INTS BIO. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
MPT0B640
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04526717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526717.